Siklos
hydroxycarbamide · Theravia
AUTHORISED IN THE EUWhat Siklos is used for
Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Siklos
- Active substance
- hydroxycarbamide
- Disease area
- Anemia, Sickle Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX05
- Marketing authorisation holder
- Theravia
- Authorised in the EU since
- 2007
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Siklos used for?
Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.
What is the active substance in Siklos?
Siklos contains hydroxycarbamide.
Who makes Siklos?
The EU marketing authorisation holder is Theravia.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU